Indirect treatment comparison of blinatumomab versus inotuzumab ozogamicin for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy.

Abstract

e19000Background: Blinatumomab (BLIN) and inotuzumab ozogamicin (INO) have demonstrated improved outcomes against standard of care (SOC) among adult patients with relapsed or refractory acute lymph...